Neuren Pharmaceuticals Limited

ASX:NEU Rapport sur les actions

Capitalisation boursière : AU$1.7b

Neuren Pharmaceuticals Résultats passés

Passé contrôle des critères 5/6

Neuren Pharmaceuticals a connu une croissance annuelle moyenne de ses bénéfices de 80.5%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 35.4% par an. Les revenus ont augmenté de en hausse à un taux moyen de 82% par an. Le rendement des capitaux propres de Neuren Pharmaceuticals est 53.5% et ses marges nettes sont de 60.7%.

Informations clés

80.5%

Taux de croissance des bénéfices

79.9%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie31.2%
Taux de croissance des recettes82.0%
Rendement des fonds propres53.5%
Marge nette60.7%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08
Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24
Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14
Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31
Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03
Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05
Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02
Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18
Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02
Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31
Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31
Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03
We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19
Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04
Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Ventilation des recettes et des dépenses

Comment Neuren Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

ASX:NEU Recettes, dépenses et bénéfices (AUD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 2419311750
31 Mar 2421313760
31 Dec 2323215760
30 Sep 2315510650
30 Jun 23785540
31 Mar 23472840
31 Dec 2215030
30 Sep 229-330
30 Jun 223-730
31 Mar 223-730
31 Dec 213-820
30 Sep 212-1020
30 Jun 211-1220
31 Mar 211-1120
31 Dec 201-920
30 Sep 201-820
30 Jun 200-820
31 Mar 200-920
31 Dec 190-1120
30 Sep 197-620
30 Jun 1914-120
31 Mar 1914120
31 Dec 1814320
30 Sep 187320
30 Jun 181310
31 Mar 181320
31 Dec 171320
30 Sep 172-220
30 Jun 173-820
31 Mar 173-1020
31 Dec 163-1220
30 Sep 162-1420
30 Jun 160-1530
31 Mar 161-1430
31 Dec 152-1330
30 Sep 152-1130
30 Jun 153-930
31 Mar 153-930
31 Dec 143-830
30 Sep 143-1020
30 Jun 143-1220
31 Mar 144-1120
31 Dec 135-1020

Des revenus de qualité: NEU a des bénéfices de haute qualité.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de NEU sont inférieures à celles de l'année dernière NEU. (60.7%) sont inférieures à celles de l'année dernière (70.3%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: NEU est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de 80.5% par an.

Accélération de la croissance: La croissance des bénéfices de NEU au cours de l'année écoulée ( 113.1% ) dépasse sa moyenne sur 5 ans ( 80.5% par an).

Bénéfices par rapport au secteur d'activité: La croissance des bénéfices NEU au cours de l'année écoulée ( 113.1% ) a dépassé celle du secteur Pharmaceuticals 46.5%.


Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de NEU ( 53.5% ) est considéré comme exceptionnel.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé